PUBLISHER: The Business Research Company | PRODUCT CODE: 1210200
PUBLISHER: The Business Research Company | PRODUCT CODE: 1210200
Arthritis Monoclonal Antibodies Global Market Report 2023
“Arthritis Monoclonal Antibodies Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on arthritis monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for arthritis monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The arthritis monoclonal antibodies market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Scope
Markets Covered:
1) By Drug: Remicade; Humira; Enbrel; Rituxan; Orencia; Actemra; Simponi; Cimzia; Remsima
2) By Application: Rheumatoid Arthritis; Osteoarthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Fibromyalgia; Other Applications
3) By End-Use: Hopitals; Research Institutes; Other End-Users
Companies Mentioned: Johnson & Johnson; Roche; Novartis; Pfizer Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Executive Summary
Major players in the arthritis monoclonal antibodies market are: Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC, and Mylan N.V.
The global arthritis monoclonal antibodies market is expected to grow from $44.14 billion in 2021 to $49.44 billion in 2022 at a compound annual growth rate (CAGR) of 12.07.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The arthritis monoclonal antibodies market is expected to reach $66.45 billion in 2026 at a CAGR of 7.7%.
The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Arthritis monoclonal antibodies refer to a class of sophisticated and useful biologic medicines used to treat rheumatoid arthritis and other immune-mediated inflammatory conditions. They inhibit the inflammatory protein interleukin-6, which reduces arthritis-related joint pain and swelling as well as other inflammation-related symptoms. In order to prevent the body from rejecting the new organ after surgery, they reduce the body's defence mechanism.
The main types of drugs in arthritis monoclonal antibodies are remicade, humira, enbrel, rituxan, orencia, actemra, simponi, cimzia, and remsima. REMICADE is a prescription drug for persons with slightly too severely active Crohn's disease who haven't had success with other treatments. The different applications include rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, and others and involve various sectors such as hospitals, research institutes, and others.
The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Centre for Disease Control and Prevention (CDC), in 2020, the adult percentage of arthritis is 23% in the USA which varies by country and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1%, and the worldwide estimates of osteoarthritis include 9.6% of men and 18% of women. The increased prevalence of arthritis and the demand for personalized medicine are increasing the demand for the arthritis monoclonal antibody market.
The high cost of monoclonal antibodies is expected to hamper the global arthritis monoclonal antibody market. According to the American Journal of Managed Care (AJMC), a survey was conducted to know the average price of monoclonal antibodies approved in the last 20 years by the FDA across disease states and found that the average annual price of 1-year treatment for each monoclonal antibody indication was $96,731. The high costs of these antibodies are basically due to the cost incurred in development and production. High costs of monoclonal antibodies are therefore expected to limit the market growth.
The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target specific and have good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.
In May 2020, AbbVie acquired Allergan for $63 billion. AbbVie is a global biopharmaceutical company whose key therapeutic areas include Immunology and Neuroscience. It is now significantly expanding its revenue base and maintaining its position in immunology by acquiring Allergan. Allergan is a global pharmaceutical leader that manufactures devices, biologics, and surgical and regenerative medicinal products all across the world.
The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the arthritis monoclonal antibodies market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).
The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.
The arthritis monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Table of Contents
1. Executive Summary
2. Arthritis Monoclonal Antibodies Market Characteristics
3. Arthritis Monoclonal Antibodies Market Trends And Strategies
4. Arthritis Monoclonal Antibodies Market - Macro Economic Scenario
4.1 COVID-19 Impact On Arthritis Monoclonal Antibodies Market
4.2 Ukraine-Russia War Impact On Arthritis Monoclonal Antibodies Market
4.3 Impact Of High Inflation On Arthritis Monoclonal Antibodies Market
5. Arthritis Monoclonal Antibodies Market Size And Growth
- 5.1. Global Arthritis Monoclonal Antibodies Historic Market, 2017-2022, $ Billion
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints On The Market
- 5.2. Global Arthritis Monoclonal Antibodies Forecast Market, 2022-2027F, 2032F, $ Billion
- 5.2.1. Drivers Of The Market
- 5.2.2. Restraints On the Market
6. Arthritis Monoclonal Antibodies Market Segmentation
- 6.1. Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Remicade
- Humira
- Enbrel
- Rituxan
- Orencia
- Actemra
- Simponi
- Cimzia
- Remsima
- 6.2. Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Rheumatoid Arthritis
- Osteoarthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Fibromyalgia
- Others
- 6.3. Global Arthritis Monoclonal Antibodies Market, Segmentation By End-use, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hopitals
- Research Institutes
- Others
7. Arthritis Monoclonal Antibodies Market Regional And Country Analysis
- 7.1. Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 7.2. Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8. Asia-Pacific Arthritis Monoclonal Antibodies Market
- 8.1. Asia-Pacific Arthritis Monoclonal Antibodies Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 8.3. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
9. China Arthritis Monoclonal Antibodies Market
- 9.1. China Arthritis Monoclonal Antibodies Market Overview
- 9.2. China Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
- 9.3. China Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
10. India Arthritis Monoclonal Antibodies Market
- 10.1. India Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 10.2. India Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11. Japan Arthritis Monoclonal Antibodies Market
- 11.1. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 11.2. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12. Australia Arthritis Monoclonal Antibodies Market
- 12.1. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 12.2. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13. Indonesia Arthritis Monoclonal Antibodies Market
- 13.1. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 13.2. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14. South Korea Arthritis Monoclonal Antibodies Market
- 14.1. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 14.2. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15. Western Europe Arthritis Monoclonal Antibodies Market
- 15.1. Western Europe Arthritis Monoclonal Antibodies Market Overview
- 15.2. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 15.3. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16. UK Arthritis Monoclonal Antibodies Market
- 16.1. UK Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 16.2. UK Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17. Germany Arthritis Monoclonal Antibodies Market
- 17.1. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 17.2. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18. France Arthritis Monoclonal Antibodies Market
- 18.1. France Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 18.2. France Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19. Eastern Europe Arthritis Monoclonal Antibodies Market
- 19.1. Eastern Europe Arthritis Monoclonal Antibodies Market Overview
- 19.2. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 19.3. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20. Russia Arthritis Monoclonal Antibodies Market
- 20.1. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 20.2. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21. North America Arthritis Monoclonal Antibodies Market
- 21.1. North America Arthritis Monoclonal Antibodies Market Overview
- 21.2. North America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 21.3. North America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22. USA Arthritis Monoclonal Antibodies Market
- 22.1. USA Arthritis Monoclonal Antibodies Market Overview
- 22.2. USA Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 22.3. USA Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23. South America Arthritis Monoclonal Antibodies Market
- 23.1. South America Arthritis Monoclonal Antibodies Market Overview
- 23.2. South America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 23.3. South America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24. Brazil Arthritis Monoclonal Antibodies Market
- 24.1. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 24.2. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25. Middle East Arthritis Monoclonal Antibodies Market
- 25.1. Middle East Arthritis Monoclonal Antibodies Market Overview
- 25.2. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 25.3. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26. Africa Arthritis Monoclonal Antibodies Market
- 26.1. Africa Arthritis Monoclonal Antibodies Market Overview
- 26.2. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- 26.3. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
27. Arthritis Monoclonal Antibodies Market Competitive Landscape And Company Profiles
- 27.1. Arthritis Monoclonal Antibodies Market Competitive Landscape
- 27.2. Arthritis Monoclonal Antibodies Market Company Profiles
- 27.2.1. Johnson & Johnson
- 27.2.1.1. Overview
- 27.2.1.2. Products and Services
- 27.2.1.3. Strategy
- 27.2.1.4. Financial Performance
- 27.2.2. Roche
- 27.2.2.1. Overview
- 27.2.2.2. Products and Services
- 27.2.2.3. Strategy
- 27.2.2.4. Financial Performance
- 27.2.3. Novartis
- 27.2.3.1. Overview
- 27.2.3.2. Products and Services
- 27.2.3.3. Strategy
- 27.2.3.4. Financial Performance
- 27.2.4. Pfizer Inc
- 27.2.4.1. Overview
- 27.2.4.2. Products and Services
- 27.2.4.3. Strategy
- 27.2.4.4. Financial Performance
- 27.2.5. AbbVie Inc.
- 27.2.5.1. Overview
- 27.2.5.2. Products and Services
- 27.2.5.3. Strategy
- 27.2.5.4. Financial Performance
- 27.2.1. Johnson & Johnson
28. Arthritis Monoclonal Antibodies Pipeline Analysis
29. Key Mergers And Acquisitions In The Arthritis Monoclonal Antibodies Market
30. Arthritis Monoclonal Antibodies Market Future Outlook and Potential Analysis
31. Appendix
- 31.1. Abbreviations
- 31.2. Currencies
- 31.3. Historic And Forecast Inflation Rates
- 31.4. Research Inquiries
- 31.5. The Business Research Company
- 31.6. Copyright And Disclaimer
